23 May 2016 - The agenda for the 23-26 May 2016 CHMP meeting is now available.

The CHMP is scheduled to issue initial opinions for the following new medicines/combination products:

• Sofosbuvir with velpatasvir for hepatitis C
• Ixazomib citrate for multiple myeloma
• Saxagliptin hydrochloride with dapagliflozin propanediol monohydrate for type 2 diabetes mellitus
• Grazoprevir with elbasvir for hepatitis C

For more details, go to: http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2016/05/WC500206954.pdf